Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Development of Inactivated FAKHRAVAC® Vaccine against SARS-CoV-2 Virus: Preclinical Study in Animal Models.
Ghasemi S, Naderi Saffar K, Ebrahimi F, Khatami P, Monazah A, Alizadeh GA, Ettehadi HA, Rad I, Nojehdehi S, Kehtari M, Kouhkan F, Barjasteh H, Moradi S, Ghorbani MH, Khodaie A, Papizadeh M, Najafi R, Naghneh E, Sadeghi D, Karimi Rahjerdi A. Ghasemi S, et al. Among authors: monazah a. Vaccines (Basel). 2021 Nov 3;9(11):1271. doi: 10.3390/vaccines9111271. Vaccines (Basel). 2021. PMID: 34835202 Free PMC article.
Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial.
Ahi M, Hamidi Farahani R, Basiri P, Karimi Rahjerdi A, Sheidaei A, Gohari K, Rahimi Z, Gholami F, Moradi M, Ghafoori Naeeni F, Saffar KN, Ghasemi S, Barati B, Moradi S, Monazah A, Pouranvari F, Forooghizadeh M. Ahi M, et al. Among authors: monazah a. Vaccines (Basel). 2022 Oct 26;10(11):1800. doi: 10.3390/vaccines10111800. Vaccines (Basel). 2022. PMID: 36366308 Free PMC article.
Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.
Gholami F, Hamidi Farahani R, Karimi Rahjerdi A, Ahi M, Sheidaei A, Gohari K, Rahimi Z, Ansarifar A, Basiri P, Moradi M, Jahangiri A, Naderi K, Ghasemi S, Khatami P, Honari M, Khodaverdloo S, Shooshtari M, Mehr Azin H, Moradi S, Shafaghi B, Allahyari H, Monazah A, Khodaei Poor A, Taghva Z, Bakhshande H, Karimi Nia M, Solaymani Dodaran M, Forooghizade M. Gholami F, et al. Among authors: monazah a. BMC Infect Dis. 2023 Feb 24;23(1):118. doi: 10.1186/s12879-023-08079-1. BMC Infect Dis. 2023. PMID: 36829111 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18-55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial.
Ansarifar A, Farahani RH, Rahjerdi AK, Ahi M, Sheidaei A, Gohari K, Rahimi Z, Gholami F, Basiri P, Moradi M, Jahangiri A, Naderi K, Ghasemi S, Khatami P, Honari M, Khodaverdloo S, Shooshtari M, Azin HM, Moradi S, Shafaghi B, Allahyari H, Monazah A, Poor AK, Bakhshande H, Taghva Z, Nia MK, Dodaran MS, Foroughizadeh M. Ansarifar A, et al. Among authors: monazah a. Vaccine X. 2023 Oct 27;15:100401. doi: 10.1016/j.jvacx.2023.100401. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37941802 Free PMC article.